An Oral-Fluid THC Meta-Analysis Separated Bivariate Associations From Adjusted Findings

A 2024 individual-participant meta-analysis found that some oral-fluid THC associations changed after statistical adjustment. Dose, use frequency and inhaled rather than ingested administration remained associated with higher concentrations, while some other associations appeared only in bivariate analyses.

The pooled data contained repeated observations

Seven controlled-administration studies contributed 1,157 observations. That is an observation count, not a count of 1,157 different participants. The analysis required individual concentration data at multiple time points and confirmatory measurements, which shaped the eligible evidence.

Adjustment narrowed the interpretation

Sex and a collection-device comparison were significant only in the reported bivariate analyses. Their disappearance from the adjusted findings limits an assertion of an independently demonstrated effect. It does not prove those variables never matter under other designs or conditions.

The concentration distributions were widely spread

Oral-fluid THC declined over time but remained dispersed and positively skewed at each time point. Most studies did not observe participants beyond 24 hours, while one documented later positives. These features limit using one concentration as an exact clock or impairment measure.

Interpreting the evidence

The useful inference preserves the model, variables and sampling schedule. An unadjusted association is not automatically an independent cause of a result. This synthesis does not supply a reliable reverse calculation of use time or a personal impairment threshold.

Related reading: interpreting cannabis tolerance claims.

Research reference

Scott Macdonald; Jinhui Zhao (2024). Concentrations of Delta 9-tetrahydrocannabinol (THC) in oral fluid at different time points after use: An individual participant meta-analysis. Heliyon. doi:10.1016/j.heliyon.2024.e39873.

This discussion draws on the abstract and introductory material in the supplied research synthesis.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

APD371 Maintained a Pain-Response Effect for Five Days in a Preclinical Development Study

A 2017 drug-discovery report described APD371, a selective CB2 agonist, maintaining its effect during a five-day rat osteoarthritis-pain protocol. That short preclinical finding is different from established long-term clinical efficacy. The report concerned selection of a development candidate The authors considered receptor efficacy, pharmacokinetics and pharmaceutical properties alongside an oral…

Spread the love

Read Article: APD371 Maintained a Pain-Response Effect for Five Days in a Preclinical Development Study

Two Biased CB2 Agonists Had Different Durability in a Rat Osteoarthritis Experiment

A 2021 rat study found sustained pain-response effects with JWH133 while another CB2 agonist lost efficacy after two days under its repeated-treatment protocol. Shared receptor targeting did not establish equal durability. The compounds were compared in a defined model The experiment used chemically induced osteoarthritis and measured pressure responses and…

Spread the love

Read Article: Two Biased CB2 Agonists Had Different Durability in a Rat Osteoarthritis Experiment

An Acute Cannabis Review Treated Neurocognitive Response as a Multi-Factor Question

A 2021 review argued that acute neurocognitive responses to cannabis vary with biological, pharmacological and exposure-related factors. A product label or use-frequency category alone cannot capture all the determinants discussed. The review considered interacting sources of variation It discussed brain-network activity, formulation, use frequency and differences between therapeutic and recreational…

Spread the love

Read Article: An Acute Cannabis Review Treated Neurocognitive Response as a Multi-Factor Question

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us